Stereotaxis (STXS) Non-Current Debt (2010 - 2021)

Stereotaxis (STXS) reported Non-Current Debt of $243617.0 for Q1 2021, down 74.97% quarter-over-quarter from $973252.0 in Q4 2020.

Stereotaxis (STXS) Non-Current Debt (2010 - 2021) Analysis & Trends

Stereotaxis (STXS) has 9 years of Non-Current Debt data on file, last reported at $243617.0 in Q1 2021.

Non-Current Debt for Q1 2021 came in at $243617.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $243617.0 (changed N/A YoY), and the FY2020 annual result was $973252.0, changed N/A from the prior year.
Non-Current Debt retreated to $243617.0 in Q1 2021 per STXS's latest filing, from $973252.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $1.7 million in Q3 2020 and troughed at $243617.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	-
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	14.71 Bn
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	12.50 Bn
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	-
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	202.80 Mn
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	4.58 Bn
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	1.86 Bn
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	-
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	8.62 Bn
10	Stereotaxis	180.48 Mn	165.86 Mn	3.79 Mn	-

Download Data